Effect of antidepressant drugs on dopamine D 1 and D 2 release in the nucleus accumbens of the rat

Psychopharmacology

140, 470-477

DOI: 10.1007/s002130050791

Citation Report

#	Article	IF	Citations
1	Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of Î±2-adrenergic and serotonin2Creceptors: a comparison with citalopram. European Journal of Neuroscience, 2000, 12, 1079-1095.	1.2	148
2	Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington's disease. Journal of Anatomy, 2000, 196, 597-607.	0.9	9
3	Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Molecular Psychiatry, 2000, 5, 378-388.	4.1	145
4	The Effects of Nicotine on Neural Pathways Implicated in Depression. Pharmacology Biochemistry and Behavior, 2000, 66, 79-85.	1.3	183
5	Antidepressants: past, present and future. European Journal of Pharmacology, 2000, 405, 351-363.	1.7	106
6	The role of dopamine in the mechanism of action of antidepressant drugs. European Journal of Pharmacology, 2000, 405, 365-373.	1.7	247
7	Effects of Citalopram on Dopamine D2 Receptor Expression in the Rat Brain Striatum. Journal of Molecular Neuroscience, 2000, 14, 077-086.	1.1	12
8	The effect of repeated treatment with pramipexole on the central dopamine D 3 system. Journal of Neural Transmission, 2000, 107, 1369-1379.	1.4	24
9	Caudate Nucleus Dopamine D₂ Receptors in Depressed Suicide Victims. Neuropsychobiology, 2001, 44, 70-73.	0.9	34
10	Dopaminergic activity in transgenic mice underexpressing glucocorticoid receptors: effect of antidepressants. Neuroscience, 2001, 102, 151-158.	1.1	28
11	No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry Research, 2001, 104, 195-203.	1.7	54
12	Repeated treatment with imipramine, fluvoxamine and tranylcypromine decreases the number of escape failures by activating dopaminergic systems in a rat learned helplessness test. Life Sciences, 2001, 69, 1919-1926.	2.0	38
13	Chronic desipramine treatment selectively potentiates somatostatin-induced dopamine release in the nucleus accumbens. European Journal of Neuroscience, 2001, 14, 763-767.	1.2	41
14	Acute and Chronic Actions of a dry methanolic extract of Hypericum Perforatum and a Hyperforin-Rich Extract on Dopaminergic and Serotonergic Neurones in Rat Nucleus Accumbens. Pharmacopsychiatry, 2001, 34, 119-126.	1.7	47
15	Effect of repeated treatment with tianeptine and fluoxetine on central dopamine D2/D3 receptors. Behavioural Pharmacology, 2002, 13, 127-138.	0.8	29
16	Pharmacogenetics in affective disorders. European Journal of Pharmacology, 2002, 438, 117-128.	1.7	55
17	Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling. Journal of Psychiatric Research, 2002, 36, 119-129.	1.5	67
18	Antidepressant-like actions of DOV 21,947: a â€œtripleâ€•reuptake inhibitor. European Journal of Pharmacology, 2003, 461, 99-104.	1.7	135

#	Article	IF	Citations
19	D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder. European Neuropsychopharmacology, 2003, 13, 313-320.	0.3	50
20	Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology, 2003, 44, 903-910.	2.0	227
21	Antidepressant drug treatment induces Arc gene expression in the rat brain. Neuroscience, 2003, 121, 975-982.	1.1	79
22	Chronic, but Not Acute, Clomipramine or Fluoxetine Treatment Reduces the Spontaneous Firing Rate in the Mesoaccumbens Neurons of the Rat. Neuropsychobiology, 2003, 48, 116-123.	0.9	10
23	S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: III. Actions in Models of Potential Antidepressive and Anxiolytic Activity in Comparison with Ropinirole. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 936-950.	1.3	48
24	Effects of fluoxetine on dopamine D2 receptors in the human brain: a positron emission tomography study with [11C]raclopride. International Journal of Neuropsychopharmacology, 2004, 7, 431-439.	1.0	29
25	ATF2, A Member of the CREB/ATF Family of Transcription Factors, in Chronic Stress and Consequent to Antidepressant Treatment: Animal Models and Human Post-Mortem Brains. Neuropsychopharmacology, 2004, 29, 589-597.	2.8	20
26	Invited review: the evolution of antidepressant mechanisms. Fundamental and Clinical Pharmacology, 2004, 18, 1-21.	1.0	158
27	The novel monoamine reuptake inhibitor and potential antidepressant, S33005, induces Arc gene expression in cerebral cortex. European Journal of Pharmacology, 2004, 489, 179-185.	1.7	7
28	Erratum to â€œThe novel monoamine reuptake inhibitor and potential antidepressant, S33005, induces Arc gene expression in cerebral cortexâ€•[Eur. J. Pharmacol. 489 (2004) 179â€“185]. European Journal of Pharmacology, 2004, 495, 227-233.	1.7	5
29	Tyrosine depletion does not cause depressive relapse in antidepressant-treated patients. Psychopharmacology, 2004, 175, 124-6.	1.5	10
30	Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. International Journal of Neuropsychopharmacology, 2004, 7, 193-218.	1.0	213
31	Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience, 2004, 128, 597-604.	1.1	219
32	Neuronal cell lines transfected with the dopamine D2 receptor gene promoter as a model for studying the effects of antidepressant drugs. Molecular Brain Research, 2004, 128, 75-82.	2.5	17
33	Neurobiology of Depression. , 2005, , 189-210.		0
34	Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment. Journal of Neurochemistry, 2005, 94, 875-883.	2.1	63
35	Nicotine produces antidepressant-like actions: Behavioral and neurochemical evidence. European Journal of Pharmacology, 2005, 515, 128-133.	1.7	15
38	Lack of Effect of Tyrosine Depletion on Mood in Recovered Depressed Women. Neuropsychopharmacology, 2005, 30, 786-791.	2.8	24

#	Article	IF	Citations
39	Antidepressant-Like Effect of D2/3 Receptor-, but not D4 Receptor-Activation in the Rat Forced Swim Test. Neuropsychopharmacology, 2005, 30, 1257-1268.	2.8	74
40	Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects?. European Neuropsychopharmacology, 2006, 16, S625-S632.	0.3	35
41	The D2 dopamine receptor (DRD2) gene is associated with co-morbid depression, anxiety and social dysfunction in untreated veterans with post-traumatic stress disorder. European Psychiatry, 2006, 21, 180-185.	0.1	126
42	Dopamine D3 receptor antisense oligodeoxynucleotide potentiates imipramine-induced dopaminergic behavioural supersensitivity. Behavioural Pharmacology, 2006, 17, 101-106.	0.8	4
43	Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats. Brain Research, 2006, 1117, 206-212.	1.1	16
44	Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. , 2006, 110, 135-370.		483
45	Neurochemistry of the Nucleus Accumbens and its Relevance to Depression and Antidepressant Action in Rodents. Current Neuropharmacology, 2006, 4, 277-291.	1.4	185
46	Fluvoxamine Treatment and D2 Receptors: a Pet Study on OCD Drug-NaÃ¯ve Patients. Neuropsychopharmacology, 2007, 32, 197-205.	2.8	65
47	Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behavioural Brain Research, 2007, 184, 133-141.	1.2	113
48	Involvement of dopamine (DA)/serotonin (5-HT)/sigma (Ïƒ) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist. Brain Research Bulletin, 2007, 74, 58-65.	1.4	45
49	Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study. Synapse, 2007, 61, 72-77.	0.6	42
50	Extrastriatal D2 and striatal D2 receptors in depressive illness: Pilot PET studies using [11C]FLB 457 and [11C]raclopride. Journal of Affective Disorders, 2007, 101, 113-122.	2.0	48
51	Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. European Journal of Pharmacology, 2007, 568, 177-185.	1.7	116
52	Possible involvement of sigmaâ€1 receptors in the antiâ€immobility action of bupropion, a dopamine reuptake inhibitor. Fundamental and Clinical Pharmacology, 2008, 22, 387-394.	1.0	30
53	Dopamine receptor gene expression in human amygdaloid nuclei: Elevated D4 receptor mRNA in major depression. Brain Research, 2008, 1207, 214-224.	1.1	49
54	Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST). European Neuropsychopharmacology, 2008, 18, 271-277.	0.3	37
55	Selegilin Exerts Antidepressant-Like Effects During the Forced Swim Test in Adrenocorticotropic Hormoneâ€"Treated Rats. Journal of Pharmacological Sciences, 2008, 106, 639-644.	1.1	9
56	Early deprivation leads to long-term reductions in motivation for reward and 5-HT1A binding and both effects are reversed by fluoxetine. Neuropharmacology, 2009, 56, 692-701.	2.0	67

#	Article	IF	Citations
57	Prospect of a Dopamine Contribution in the Next Generation of Antidepressant Drugs: The Triple Reuptake Inhibitors. Current Drug Targets, 2009, 10, 1069-1084.	1.0	73
58	Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT1A agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist apomorphine. Brain Research, 2010, 1335, 24-34.	1.1	7
59	Retinoid X Receptor Gamma Control of Affective Behaviors Involves Dopaminergic Signaling in Mice. Neuron, 2010, 66, 908-920.	3.8	65
60	Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants. Journal of Psychopharmacology, 2010, 24, 709-716.	2.0	25
61	Evidence of involvement of the human Par-4 (PAWR) gene in major depressive disorder. World Journal of Biological Psychiatry, 2011, 12, 288-295.	1.3	3
62	Expression of the Dopaminergic D1 and D2 Receptors in the Anterior Cingulate Cortex in a Model of Neuropathic Pain. Molecular Pain, 2011, 7, 1744-8069-7-97.	1.0	25
63	Effects of antidepressant drug treatment and psychotherapy on striatal and thalamic dopamine D_{2/3} receptors in major depressive disorder studied with [¹¹C]raclopride PET. Journal of Psychopharmacology, 2011, 25, 1329-1336.	2.0	33
64	Chronic Fluoxetine Selectively Upregulates Dopamine D1-Like Receptors in the Hippocampus. Neuropsychopharmacology, 2012, 37, 1500-1508.	2.8	44
65	Antidepressant and anxiolytic effects of amentoflavone isolated from Cnestis ferruginea in mice. Pharmacology Biochemistry and Behavior, 2012, 103, 322-331.	1.3	90
66	Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats. European Neuropsychopharmacology, 2012, 22, 290-299.	0.3	24
67	Role for monoaminergic systems in the antidepressant-like effect of ethanol extracts from Hemerocallis citrina. Journal of Ethnopharmacology, 2012, 139, 780-787.	2.0	68
68	Receptor targets for antidepressant therapy in bipolar disorder: An overview. Journal of Affective Disorders, 2012, 138, 222-238.	2.0	39
69	Dopamine D3 receptor as a new pharmacological target for the treatment of depression. European Journal of Pharmacology, 2013, 719, 25-33.	1.7	115
70	Antidepressant-like effect of lemon essential oil is through a modulation in the levels of norepinephrine, dopamine, and serotonin in mice: Use of the tail suspension test. Journal of Functional Foods, 2013, 5, 370-379.	1.6	38
71	Potential of novel phytoecdysteroids isolated from Vitex doniana in the treatment depression: Involvement of monoaminergic systems. Pharmacology Biochemistry and Behavior, 2014, 127, 90-100.	1.3	14
72	Dopamine receptor D3 deficiency results in chronic depression and anxiety. Behavioural Brain Research, 2014, 274, 186-193.	1.2	66
73	Reinforcement learning in depression: A review of computational research. Neuroscience and Biobehavioral Reviews, 2015, 55, 247-267.	2.9	154
74	Effects of palatable cafeteria diet on cognitive and noncognitive behaviors and brain neurotrophinsâ€™ levels in mice. Metabolic Brain Disease, 2015, 30, 1073-1082.	1.4	38

#	Article	IF	Citations
75	Not only serotonergic system, but also dopaminergic system involved in albiflorin against chronic unpredictable mild stress-induced depression-like behavior in rats. Chemico-Biological Interactions, 2015, 242, 211-217.	1.7	34
76	Dopamine D2/D3 but not dopamine D1 receptors are involved in the rapid antidepressant-like effects of ketamine in the forced swim test. Behavioural Brain Research, 2015, 279, 100-105.	1.2	57
77	Investigation of the antidepressant effects of exopolysaccharides obtained from Marasmius androsaceus fermentation in a mouse model. Molecular Medicine Reports, 2016, 13, 939-946.	1.1	10
78	Dysregulation of Striatal Dopamine Receptor Binding in Suicide. Neuropsychopharmacology, 2017, 42, 974-982.	2.8	45
79	Paecilomyces tenuipes extract prevents depression-like behaviors in chronic unpredictable mild stress-induced rat model via modulation of neurotransmitters. Molecular Medicine Reports, 2017, 16, 2172-2178.	1.1	9
80	Dopamine and serotonin contribute to Paecilomyces hepiali against chronic unpredictable mild stress induced depressive behavior in Sprague Dawley rats. Molecular Medicine Reports, 2017, 16, 5675-5682.	1.1	12
81	Error-related Brain Activity as a Treatment Moderator and Index of Symptom Change during Cognitive-Behavioral Therapy or Selective Serotonin Reuptake Inhibitors. Neuropsychopharmacology, 2018, 43, 1355-1363.	2.8	18
82	Mechanism of Action of ECT. , 2019, , 13-23.		3
83	Antidepressant Withdrawal and Rebound Phenomena. Deutsches Ärzteblatt International, 2019, 116, 355-361.	0.6	51
84	Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults. Brain Research, 2019, 1723, 146398.	1.1	16
85	Voluntary Wheel Running Reverses Deficits in Social Behavior Induced by Chronic Social Defeat Stress in Mice: Involvement of the Dopamine System. Frontiers in Neuroscience, 2019, 13, 256.	1.4	10
86	Î²-Carbolines found in cigarette smoke elevate intracranial self-stimulation thresholds in rats. Pharmacology Biochemistry and Behavior, 2020, 198, 173041.	1.3	6
87	Neuropsychiatric Disorders in Parkinsonâ€™s Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?. Frontiers in Neuroscience, 2020, 14, 25.	1.4	30
89	Antidepressants: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy. , 2021, , 1-19.		0
90	Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence. Current Medical Research and Opinion, 2021, 37, 1233-1248.	0.9	3
91	Dopamine and Depression. , 2005, , 199-214.		11
92	New Hypotheses to Guide Future Antidepressant Drug Development. Handbook of Experimental Pharmacology, 2004, , 519-563.	0.9	2
93	The Dopamine D3 Receptor and Its Implication in Neuropsychiatry Disorders and Their Treatments. Handbook of Experimental Pharmacology, 2002, , 185-221.	0.9	2

#	Article	IF	Citations
95	Neuroendocrine markers of depression and antidepressant drug action. , 2001, , 95-107.		2
97	D1 receptor-expressing neurons in ventral tegmental area alleviate mouse anxiety-like behaviors via glutamatergic projection to lateral septum. Molecular Psychiatry, 2023, 28, 625-638.	4.1	15
98	Antidepressants: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy. , 2022, , 1173-1191.		0